Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00964223 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
A Phase 4 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT00964223 is a Phase 4 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 28 participants.
The verdict
NCT00964223, a Phase 4 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
Multi-center, single-blind, randomized, comparative, split-face study. The duration of the study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin and benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. After visit 3, subjects will commence application of clindamycin and benzoyl peroxide gel to the entire face for an additional 6 weeks.
Interventions
- DRUG Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)
- DRUG benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00964223
The ClinicalTrials.gov registry entry for NCT00964223 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clindamycin and benzoyl peroxide gel (Duac® Topical Gel) is the first listed.
NCT00964223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00964223 about?
NCT00964223 is a clinical study titled "A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne". Multi-center, single-blind, randomized, comparative, split-face study. The duration of the study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin and benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face fashion (allocation to left and r...
What is the current status of trial NCT00964223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2009-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00964223?
The interventions under investigation include: Clindamycin and benzoyl peroxide gel (Duac® Topical Gel) (DRUG), benzoyl peroxide and adapalene gel (EPIDUO™ Gel) (DRUG).
Who is sponsoring clinical trial NCT00964223?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.